Business Description
Carl Zeiss Meditec AG
ISIN : DE0005313704
Share Class Description:
STU:AFX: Ordinary SharesTotal Employee Number:
5,784Description
Carl Zeiss Meditec is one of the largest visioncare technology companies in the world. Its ophthalmology segment, which made up about 75% of sales in 2025, includes refractive lasers, surgical ophthalmic devices, equipment for ophthalmic diagnostics, intraocular lenses, and disposable medical instruments. With a low-teens share of the market, Zeiss is the second-largest player in the space. The microsurgery segment is composed of implants, surgical instruments, and visualization devices used during neurosurgery, spine surgery, and otolaryngology surgery. With over 60% share, Zeiss is the clear leader in this market.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.21 | |||||
Equity-to-Asset | 0.62 | |||||
Debt-to-Equity | 0.06 | |||||
Debt-to-EBITDA | 0.68 | |||||
Interest Coverage | 7.23 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 3.07 | |||||
Beneish M-Score | -2.51 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 6.2 | |||||
3-Year EBITDA Growth Rate | -9.8 | |||||
3-Year EPS without NRI Growth Rate | -23.3 | |||||
3-Year FCF Growth Rate | 8.6 | |||||
3-Year Book Growth Rate | 2.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.14 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 71.54 | |||||
9-Day RSI | 65.28 | |||||
14-Day RSI | 62.4 | |||||
3-1 Month Momentum % | 14.07 | |||||
6-1 Month Momentum % | 5.9 | |||||
12-1 Month Momentum % | -35.59 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.34 | |||||
Quick Ratio | 1.43 | |||||
Cash Ratio | 0.05 | |||||
Days Inventory | 182.87 | |||||
Days Sales Outstanding | 33.21 | |||||
Days Payable | 65.41 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.82 | |||||
Dividend Payout Ratio | 0.44 | |||||
3-Year Dividend Growth Rate | -12.6 | |||||
Forward Dividend Yield % | 1.82 | |||||
5-Year Yield-on-Cost % | 2.51 | |||||
3-Year Average Share Buyback Ratio | 0.7 | |||||
Shareholder Yield % | 2.06 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 52.18 | |||||
Operating Margin % | 8.91 | |||||
Net Margin % | 5.47 | |||||
EBITDA Margin % | 8.87 | |||||
FCF Margin % | 11.47 | |||||
OCF Margin % | 11.47 | |||||
ROE % | 5.8 | |||||
ROA % | 3.52 | |||||
ROIC % | 4.58 | |||||
3-Year ROIIC % | -23.21 | |||||
ROC (Joel Greenblatt) % | 32.42 | |||||
ROCE % | 6.88 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 23.56 | |||||
Forward PE Ratio | 21.9 | |||||
PE Ratio without NRI | 23.56 | |||||
Shiller PE Ratio | 14.14 | |||||
PEG Ratio | 5.61 | |||||
PS Ratio | 1.26 | |||||
PB Ratio | 1.34 | |||||
Price-to-Tangible-Book | 5.84 | |||||
Price-to-Free-Cash-Flow | 11.12 | |||||
Price-to-Operating-Cash-Flow | 11.12 | |||||
EV-to-EBIT | 15.04 | |||||
EV-to-Forward-EBIT | 14.06 | |||||
EV-to-EBITDA | 15.04 | |||||
EV-to-Forward-EBITDA | 9.33 | |||||
EV-to-Revenue | 1.33 | |||||
EV-to-Forward-Revenue | 1.22 | |||||
EV-to-FCF | 11.64 | |||||
Price-to-GF-Value | 0.44 | |||||
Price-to-Projected-FCF | 1.17 | |||||
Price-to-DCF (Earnings Based) | 1.41 | |||||
Price-to-DCF (FCF Based) | 0.81 | |||||
Price-to-Median-PS-Value | 0.27 | |||||
Price-to-Graham-Number | 2.28 | |||||
Earnings Yield (Greenblatt) % | 6.65 | |||||
FCF Yield % | 8.95 | |||||
Forward Rate of Return (Yacktman) % | 2.13 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Carl Zeiss Meditec AG Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,204.192 | ||
| EPS (TTM) (€) | 1.37 | ||
| Beta | 0.7454 | ||
| 3-Year Sharpe Ratio | -0.84 | ||
| 3-Year Sortino Ratio | -1.02 | ||
| Volatility % | 38.95 | ||
| 14-Day RSI | 62.4 | ||
| 14-Day ATR (€) | 1.399858 | ||
| 20-Day SMA (€) | 29.537 | ||
| 12-1 Month Momentum % | -35.59 | ||
| 52-Week Range (€) | 22.76 - 48.36 | ||
| Shares Outstanding (Mil) | 87.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Carl Zeiss Meditec AG Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Carl Zeiss Meditec AG Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| First quarter earnings conference call for 2027 | 2027-02-12 | In 181 days | ||
| First quarter earnings results for 2027 | 2027-02-12 | In 181 days | ||
| Annual report for 2026 | 2026-12-11 | In 118 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-12-11 | In 118 days | ||
| Fourth quarter earnings results for 2026 | 2026-12-11 | In 118 days | ||
| Third quarter earnings conference call for 2026 | 2026-08-06 | 30.26 (-1.94%) | ||
| Third quarter earnings results for 2026 | 2026-08-06 | 30.26 (-1.94%) | ||
| Second quarter earnings conference call for 2026 | 2026-05-12 | 25.80 (+0.70%) | ||
| Second quarter earnings results for 2026 | 2026-05-12 | 25.80 (+0.70%) | ||
| EUR 0.550000 Cash Dividend | 2026-03-27 | 25.28 (+1.77%) |
Show
Entries
Carl Zeiss Meditec AG Frequently Asked Questions
What is Carl Zeiss Meditec AG(STU:AFX)'s stock price today?
The current price of STU:AFX is €31.94. The 52 week high of STU:AFX is €48.36 and 52 week low is €22.76.
When is next earnings date of Carl Zeiss Meditec AG(STU:AFX)?
The next earnings date of Carl Zeiss Meditec AG(STU:AFX) is 2026-12-11 Est..
Does Carl Zeiss Meditec AG(STU:AFX) pay dividends? If so, how much?
The Dividend Yield %  of Carl Zeiss Meditec AG(STU:AFX) is 1.82% (As of Today), Highest Dividend Payout Ratio of Carl Zeiss Meditec AG(STU:AFX) was 0.59. The lowest was 0.19. And the median was 0.35. The  Forward Dividend Yield % of Carl Zeiss Meditec AG(STU:AFX) is 1.82%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Carl Zeiss Meditec AG
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers